Table 2.

Association between EGF+61 genotype and alleles from TKI‐treated NSCLC patients harboring EGFR‐sensitizing mutations (n = 111) and TKI treatment response

	PR		SD		DP
Response to TKI treatment	n	%	n	%	n	%	P‐value
Genotype (codominant model)
AA	23	29.5%	10	55.6%	2	13.3%	0.046
AG	42	53.8%	4	22.2%	9	60.0%
GG	13	16.7%	4	22.2%	4	26.7%
Genotype (recessive model)
AA	23	29.5%	10	55.6%	2	13.3%	0.023
AG + GG	55	70.5%	8	44.4%	13	86.7%
Genotype (dominant model)
AA + AG	65	83.3%	14	77.8%	11	73.3%	0.601
GG	13	16.7%	4	22.2%	4	26.7%
Allele frequency
A		56.4%		66.7%		43.3%	0.163
G		43.6%		33.3%		56.7%

Bold P‐values indicate P ≤ 0.05 from univariate analysis (χ² test).

DP, disease progression; PR, partial response; SD, stable disease.